Hidradenitis Suppurativa
📧 Sign up to get email alerts when something new happens for Hidradenitis Suppurativa.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-21Clinical Trial Update: Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa [Phase 4]
A Phase 4 clinical trial is planned to evaluate the efficacy and safety of secukinumab in Chinese adults with moderate-to-severe hidradeniti…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of secukinumAb in Adult Patients With Moderate to Severe Hidradenitis Suppurativa.
This document describes an ongoing long-term observational study collecting real-world data on how secukinumab is used to treat adults with …
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic
This clinical trial update describes a long-term observational study to evaluate the safety of a gene-modified regulatory T cell therapy in …
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1) [Phase 3]
Phase 3 clinical trial evaluating the efficacy and safety of topical ruxolitinib cream in hidradenitis suppurativa is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (HS) in Routine Clinical Practice in the Russian Federation
A real-world data study sponsored by Novartis to collect how secukinumab is used in adults with moderate to severe hidradenitis suppurativa …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Real-world Secukinumab Outcomes in Canadian HS Patients
A real-world study evaluating secukinumab for hidradenitis suppurativa in Canadian patients is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa [Phase 2]
Brivekimig is being studied in a Phase 2 trial for moderate to severe hidradenitis suppurativa, with recruitment currently ongoing.
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2) [Phase 3]
Phase 3 clinical trial evaluating the efficacy and safety of topical ruxolitinib cream for hidradenitis suppurativa, currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib [Phase 3]
This clinical trial update notes a rollover study for participants previously enrolled in povorcitinib trials for hidradenitis suppurativa, …
-
CLINICAL_TRIALS trial_result · 2026-04-06Clinical Trial Update: Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa [Phase 2]
Clinical trial update on the pharmacokinetics, safety, and efficacy of povorcitinib in adolescent participants with moderate to severe hidra…
-
CLINICAL_TRIALS trial_result · 2026-04-06Clinical Trial Update: Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa [Phase 1]
This clinical trial update indicates a Phase 1 study to evaluate the maximal use of ruxolitinib cream in adult and adolescent participants w…
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa [Phase 2, Phase 3]
A Phase 2/3 trial of BFB759 for moderate to severe hidradenitis suppurativa is currently recruiting, sponsored by Bluefin Biomedicine, Inc.
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab) [Phase 1]
A Phase 1 study is evaluating the concentration of Bimzelx (bimekizumab) in mature breast milk in mothers receiving treatment, and is curren…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: Assessing Short-term Treatment Satisfaction and Quality of Life in Patients With Hidradenitis Suppurativa Initiated on Secukinumab.
Clinical trial update assessing short-term treatment satisfaction and quality of life in hidradenitis suppurativa patients initiated on secu…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers
Clinical trial update notes ongoing sample collection from participants with acne, atopic dermatitis, chronic hand eczema, hidradenitis supp…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa [Phase 3]
This is a Phase 3 study to assess pharmacokinetics and safety of Bimekizumab in children and adolescents with moderate to severe hidradeniti…
-
CLINICAL_TRIALS research · 2026-03-25Clinical Trial Update: A Study With CIT-013 in HS Patients [Phase 2]
This clinical trial update reports that a Phase 2 study of CIT-013 in hidradenitis suppurativa is currently recruiting. The sponsor is Citry…
-
CLINICAL_TRIALS trial_result · 2026-03-23Clinical Trial Update: A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa [Phase 3]
It is a Phase 3 study assessing the long-term safety and efficacy of povorcitinib in participants with moderate-to-severe hidradenitis suppu…
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
This document summarizes an ongoing longitudinal observational study of patients undergoing therapy for IMISC (NCT03661866) across several i…
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa [Phase 3]
A Phase 3 clinical trial to evaluate disease activity and safety of Lutikizumab in adults and adolescents with moderate to severe hidradenit…
-
EMA approval · 2026-03-19EMA Authorised: Libmyris (adalimumab) — Stada Arzneimittel AG
EMA authorised Libmyris (adalimumab) by Stada Arzneimittel AG for multiple inflammatory diseases, expanding treatment options in rheumatoid …
-
CLINICAL_TRIALS trial_result · 2026-03-17Clinical Trial Update: The Evaluation of Injection Site Pain and Adherence in Patients Switching From a Low To High Concentration Adalimumab (AVT-02) Across Multiple Indications.
Clinical trial update evaluating injection site pain and adherence when switching from a low to high concentration AVT-02 (adalimumab) acros…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Clinical and Biological Characteristics of Hidradenitis Suppurativa
A UCSF-led clinical study investigating the clinical and biological characteristics of hidradenitis suppurativa is currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Hidradenitis Suppurativa Prospective Observational Registry and Biospecimen Repository
This ClinicalTrials.gov entry describes a prospective observational registry and biospecimen repository for hidradenitis suppurativa and is …
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1) [Phase 3]
A Phase 3 study (RECHARGE 1) to assess the efficacy, safety, and tolerability of remibrutinib in adults and adolescents with moderate to sev…